1. Search Result
Search Result
Results for "

Wistar rat

" in MedChemExpress (MCE) Product Catalog:

26

Inhibitors & Agonists

2

Biochemical Assay Reagents

2

Peptides

2

Natural
Products

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-119671

    COX Lipoxygenase Endocrinology
    BW 755C is a 5-lipoxygenase (5-LO) inhibitor with an IC50 of 5 μM. BW 755C also inhibits cyclooxygenase (COX) with IC50s of 0.65 and 1.2 μg/mL against COX-1 and COX-2, respectively .
    BW 755C
  • HY-N9737

    Others Neurological Disease
    (−)-Acutumine is a tetracyclic chloroalkaloid that exhibits selective cytotoxicity to cultured human T cells and memory-enhancing properties in the Wistar rat model .
    (−)-Acutumine
  • HY-116930

    Melatonin Receptor Metabolic Disease
    S-20928 is an antagonist for melatonin receptor through inhibition of binding of melatonin to its receptors. S-20928 enhances the 2-Deoxy-D-glucose (2DG) (HY-13966)-induced increase in blood glucose and glucagon levels in rats brain .
    S-20928
  • HY-120329

    mAChR Others
    Lu 26-046 is the agonist for muscarinic M1 receptor and M2 receptor and a weak antagonist for M3 receptor, with Ki of 0.51, 26 and 5 nM, respectively. Lu 26-046 exhibits specific stimulus property, that can be recognized by rats .
    Lu 26-046
  • HY-W039923

    Insulin Receptor Endocrinology
    β-D-Galactose pentaacetate is a negative regulator of insulin with plasma membrane penetrating ability and can be hydrolyzed by intracellular esterases. β-D-Galactose pentaacetate inhibits leucine-induced insulin release in Wistar rat islets, potentially preventing excessive insulin release in pathological conditions .
    β-D-Galactose pentaacetate
  • HY-164011

    5-HT Receptor Neurological Disease
    Alaproclate is an inhibitor for serotonin (5-HT) reuptake. Alaproclate affects mechanisms that related to cued navigation performance such as sensory, sensorimotor, or motivational factors, impairs spatial navigation ability of rats .
    Alaproclate
  • HY-119750

    Others Cardiovascular Disease
    Budralazine is a vasodilator, which dilates the vascular smooth muscle and exhibits hypotensive efficacy. Budralazine inhibits the central sympathetic nerve and exhibits an anti-tachycardic effect .
    Budralazine
  • HY-160602

    Free Fatty Acid Receptor Metabolic Disease
    CPL207280 is an orally active GPR40/FFA1 agonist with an antidiabetic effect. CPL207280 can effectively enhance glucose-stimulated insulin secretion and improve glucose tolerance in MIN6 pancreatic β-cells as well as in healthy Wistar Han rats and diabetic rat models. CPL207280 can be used for the research of type 2 diabetes .
    CPL207280
  • HY-19126

    Platelet-activating Factor Receptor (PAFR) Infection
    CL-184005 is an antagonist for platelet-activating factor (PAF), that inhibits the PAF-induced platelet aggregation with IC50 of 600 nM and 510 nM, in human and rabbit platelet-rich plasma. CL-184005 protects the rats from endotoxin-induced gastrointestinal damage and hypotension. CL-184005 exhibits potential attenuating Gram-negative bacterial sepsis .
    CL-184005
  • HY-114753

    CR-2249; XY-2401

    iGluR Neurological Disease
    Neboglamine (CR-2249; XY-2401) is a modulator for N-methyl-D-aspartate (NMDA) receptor. Neboglamine increases the levels of fos-like immunoreactivity (FLI)-positive cells in the prefrontal cortex, nucleus accumbens, and lateral septal nucleus in rat models, .restores NMDA (HY-17551) -mediated neurotransmitter release, and inhibits phencyclidine-induced hyperlocomotion .
    Neboglamine
  • HY-W013851

    Biochemical Assay Reagents Others
    EDTA-OH is a chelating agent, which forms thermodynamically stable chelates with metal ions like calcium, magnesium, iron, zinc and copper . EDTA-OH exhibits ability of phytoremediation in heavy-metal-contaminated soils . EDTA-OH is able to cross brain-blood barrier .
    EDTA-OH
  • HY-128029

    Others Metabolic Disease
    Glycogen phosphorylase-IN-1 (Compound 42) is an inhibitor for human liver glycogen phosphorylase (hlGPa) and hepatocyte glycogen-derived glucose production with IC50s of 53 and 380 nM, respectively. Glycogen phosphorylase-IN-1 reveals efficacy towards type 2 diabetes .
    Glycogen phosphorylase-IN-1
  • HY-161896

    Others Neurological Disease
    Transcription factor-IN-1 (Compound 4e) is an inhibitor for transcription factor. Transcription factor-IN-1 exhibits anticonvulsant activity by antagonism with pentylenetetrazole (PTZ) (ED50 =34.5 mg/kg). Transcription factor-IN-1 exhibits antidepressant effects in rat models .
    Transcription factor-IN-1
  • HY-W587489

    Drug Metabolite Cardiovascular Disease
    RL-603 is the metabolite of Anagrelide (HY-B0523). RL-603 exhibits platelet-lowering activity in mouse model .
    RL-603
  • HY-100827

    LF22-0542

    Bradykinin Receptor Inflammation/Immunology
    Safotibant (LF22-0542) is a selective antagonist for kinin B1 receptor (BKB1R), with Ki of 0.35 and 6.5 nM, for human and mouse BKB1R, respectively. Safotibant exhibits analgesic and anti-inflammatory property in mice model .
    Safotibant
  • HY-162511

    Dopamine Transporter Serotonin Transporter Others
    IP2015 is an inhibitor for monoamine reuptake, that inhibits the reuptake of dopamine, serotonin (5-HT), and noradrenaline. IP2015 increases release of central dopamine and peripheral nitric oxide (NO), causes the NO-mediated relaxation of erectile tissue, and thus induces erection in rat model .
    IP2015
  • HY-113587

    Nicoclonol hydrochloride

    Others Others
    Nicoclonate (hydrochloride)(Nicoclonol (hydrochloride)) is an antilipemic agent .
    Nicoclonate hydrochloride
  • HY-120381

    CAM 1189

    Cholecystokinin Receptor Neurological Disease Inflammation/Immunology
    PD 136450 (CAM 1189) is an antagonist for cholecystokinin 2 (CCK2). PD 136450 exhibits anti-secretory, anxiolytic and anti-ulcer activities, inhibits gastric acid secretion (IC50=1 mg/kg), and ameliorates the haemorrhagic lesions (IC50=4.7 mg/kg) in rats .
    PD 136450
  • HY-125625

    Renin Cardiovascular Disease
    ES 6864 is an orally active, competitive inhibitor for human renin, with an IC50 of 6.9 nM and a Ki of 7.3 nM. ES 6864 exhibits high species-specific and enzyme-specific properties. ES 6864 exhibits metabolic stability in rat tissue homogenates. ES 6864 reduces blood pressure in rats and sodium-depleted awake marmosets .
    ES 6864
  • HY-162710

    Aminopeptidase Inflammation/Immunology
    LTA4H-IN-5 (Compound H122) is an orally active inhibitor for leukotriene A4 hydrolase (LTA4H), that inhibits the LTA4H aminopeptidase and LTA4H hydrolase with IC50 of 0.38 nM and 16.93 nM. LTA4H-IN-5 exhibits good pharmacokinetic characteristics in C57 mice and ameliorates the DNBS-induced ulcerative enteritis in rat models .
    LTA4H-IN-5
  • HY-16290

    ZK 230211; BAY86 5044

    Progesterone Receptor Endocrinology
    Lonaprisan (ZK 230211; BAY86 5044) is an antagonist for progesterone receptor, with IC50 of 3.6 pM and 2.5 pM for PR-A and PR-B, respectively. Lonaprisan exhibits antiprogestagenic activity in rabbits, interrupts early pregnancy in rats, and exhibits antitumor efficacy against DMBA (HY-W011845)-induced mammary tumor. Lonaprisan reveals antiglucocorticoid and antiandrogenic effect .
    Lonaprisan
  • HY-136704

    Glutaminase Cancer
    GLS1 Inhibitor-1 (Compound 27) is an orally active inhibitor for glutaminase 1 (GLS1) with an IC50 of 0.021 μM. GLS1 Inhibitor-1 inhibits the proliferation of PC-3 with an IC50 of 0.3 nM. GLS1 Inhibitor-1 exhibits antitumor efficacy against NCI-H1703 with GI50 of 0.011 μM. GLS1 Inhibitor-1 exhibits moderate pharmacokinetic characteristics .
    GLS1 Inhibitor-1
  • HY-P1944A
    Apelin-13 TFA
    5 Publications Verification

    Apelin Receptor (APJ) Cardiovascular Disease Metabolic Disease
    Apelin-13 TFA is an endogenous ligand for the G-protein coupled receptor angiotensin II protein J (APJ), activating this G protein-coupled receptor with an EC 50 value of 0.37 nM. Apelin-13 TFA has vasodilatory and antihypertensive effects. Apelin-13 TFA also can be used for researching type 2 diabetes and metabolic syndrome .
    Apelin-13 TFA
  • HY-P1944

    Apelin Receptor (APJ) Cardiovascular Disease Metabolic Disease
    Apelin-13 is an endogenous ligand for the G-protein coupled receptor angiotensin II protein J (APJ), activating this G protein-coupled receptor with an EC 50 value of 0.37 nM. Apelin-13 is widely distributed in the central and peripheral nervous systems. Apelin-13 has vasodilatory and antihypertensive effects. Apelin-13 also can be used for researching type 2 diabetes and metabolic syndrome .
    Apelin-13
  • HY-160761

    Opioid Receptor Inflammation/Immunology
    K-Opioid receptor agonist-1 (Compound 5a) is an agonist for κ-Opioid receptor with Ki of 0.25 nM and EC50 of 2 nM. K-Opioid receptor agonist-1 is blood brain barrier (BBB) penetrate (brain/plasma ratios of 0.50 to 0.65). K-Opioid receptor agonist-1 exhibits anti-inflammatory activity in dermatitis models induced by Arachidonic acid (HY-109590) or oxazolidinone .
    K-Opioid receptor agonist-1
  • HY-161618

    JAK EGFR PI3K IGF-1R GSK-3 Inflammation/Immunology Endocrinology
    MJ04 is a selective inhibitor for Janus Kinase 3 (JAK 3) with an IC50 of 2.03 nM. MJ04 inhibits T cell differentation and inhibits the proinfammatory cytokines in Lipopolysaccharides (HY-D1056)‑induced macrophages. MJ04 exhibits good pharmacokinetic characters in mice, promotes hair growth in DHT-induced androgenetic alopecia (AGA) in athymic mice model, without significant toxicity (LD50 >2 g/kg) .
    MJ04

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: